Tranexamic acid in COVID-19 pneumonia
Hayder M. Al-kuraishy1, Ali I.
Al-Gareeb1, Natália
Cruz-Martins2,3,4,*, Gaber El-Saber
Batiha5,*
1Department of clinical pharmacology and medicine,
College of Medicine, Al-Mustansiriya University; Hayderm36@yahoo.com
(H.M.A.-K.);
Dr.alialgareeb78@yahoo.com
(A.I.A.-G.)
2Faculty of Medicine, University of Porto, 4200-319
Porto, Portugal
3Institute for Research and Innovation in Health
(i3S), University of Porto, 4200-135 Porto, Portugal
4Laboratory of Neuropsychophysiology, Faculty of
Psychology and Education Sciences, University of Porto, 4200-135 Porto,
Portugal
5Department of Pharmacology and Therapeutics, Faculty
of Veterinary Medicine, Damanhour University, Damanhour 22511,
AlBeheira, Egypt;
gaberbatiha@gmail.com
Corresponding authors:
ncmartins@med.up.pt
(N.C.-M.);
gaberbatiha@gmail.com
(G.E.-S.B.)